Drug intelligence / Profile preview

SY-401

Development stage: Preclinical
Lead developer: Seinda Pharmaceutical
Administration: Ophthalmic

Overview

SY-401 is an early-stage ophthalmic drug candidate being developed by Seinda (specifically through its affiliate Guangdong Shengze Kanghua Biopharmaceutical) for the treatment of undisclosed retinal diseases. Currently in the lead identification and discovery phase, the drug is part of a specialized pipeline focused on eye diseases. Detailed information regarding its specific biological target, molecular modality, and mechanism of action remains proprietary and has not yet been publicly disclosed.

Beyond the preview

Go deeper on SY-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-401.

Explore the full profile